Sign up to get helpful information about RYSTIGGO

US-RZ-2400098

hero image

REACH HIGHER

with RYSTIGGO*

 

for adults with GENERALIZED MYASTHENIA GRAVIS (gMG) who are anti-AChR or anti-MuSK antibody positive

Ask your doctor about RYSTIGGO

*Based on MG-ADL and QMG results at Day 43 vs placebo in the MycarinG clinical trial. Results may vary. No head-to-head trials were conducted.

VIEW RESULTS

AChR=acetylcholine receptor; MG-ADL=Myasthenia Gravis Activities of Daily Living; MuSK=muscle-specific tyrosine kinase; QMG=Quantitative Myasthenia Gravis.

Targeted gMG treatment

 

RYSTIGGO (rozanolixizumab-noli) works by targeting FcRn, a protein in your immune system which can extend the life of harmful antibodies that can cause gMG.

SEE IT IN ACTION
FcRn=Neonatal Fc receptor.

Reduces gMG symptoms

 

In a clinical trial, participants taking RYSTIGGO saw significant improvements in activities of daily living as measured by MG-ADL.

VIEW TRIAL RESULTS
Individual results may vary, and not all people will experience improvements. MG-ADL=Myasthenia Gravis Activities of Daily Living.

Rapid improvement by the end of Week 6

 

RYSTIGGO significantly improved MG-ADL scores by the end of the 6-week treatment period. Some participants saw improvement as early as 1 week after the first dose.

VIEW THE DATA
35% (23 out of 66 people) of the 7 mg/kg group and 38% (25 out of 66) of the 10 mg/kg group, compared to 24% (16 out of 67) of the placebo group, as determined by improvement in MG-ADL score.
FcRn=Neonatal Fc receptor.
Individual results may vary, and not all people will experience improvements. MG-ADL=Myasthenia Gravis Activities of Daily Living.
35% (23 out of 66 people) of the 7 mg/kg group and 38% (25 out of 66) of the 10 mg/kg group, compared to 24% (16 out of 67) of the placebo group, as determined by improvement in MG-ADL score.
MuSK

The first FDA-approved treatment for

anti-MuSK antibody-positive gMG

LEARN ABOUT ANTI-MuSK gMG
Infusion in about 15 minutes

Administered in minutes

Once prepared by a healthcare professional, RYSTIGGO subcutaneous (under the surface of the skin) infusions may be completed in about 15 minutes.

WHAT TO EXPECT

Infusion time may vary.

ONWARD™ personalized support designed to move you forward.

Here for you throughout your treatment

ONWARD® provides personalized support, including help to understand coverage and financial options, tools to help you track symptoms, and guidance when starting and continuing treatment.

LEARN MORE

ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.